JD Health's stock plummeted 5.31% during intraday trading on Monday, as new regulations on online sales of GLP-1 weight loss drugs and broad sector weakness pressured the online healthcare platform.
New regulations that took effect require purchasers of GLP-1 weight loss drugs to present paper prescriptions issued by physical hospitals, invalidating prescriptions from internet hospitals. This has led multiple pharmacies to delist related products from JD and other platforms, directly suppressing the company's online pharmaceutical sales business.
The Internet and Direct Marketing Retail sector faced broad selling pressure, with peers including Ali Health, PA Good Doctor, JD Group, Alibaba, and Meituan also declining, amplifying the downward move in JD Health's shares.
Comments